Cargando…

SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation

Chronic lymphocytic leukemia (CLL) is characterized by low CD20 expression, in part explained by an epigenetic-driven downregulation triggered by mutations of the NOTCH1 gene. In the present study, by taking advantage of a wide and well-characterized CLL cohort (n=537), we demonstrate that CD20 expr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pozzo, Federico, Bittolo, Tamara, Tissino, Erika, Vit, Filippo, Vendramini, Elena, Laurenti, Luca, D’Arena, Giovanni, Olivieri, Jacopo, Pozzato, Gabriele, Zaja, Francesco, Chiarenza, Annalisa, Di Raimondo, Francesco, Zucchetto, Antonella, Bomben, Riccardo, Rossi, Francesca Maria, Del Poeta, Giovanni, Dal Bo, Michele, Gattei, Valter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634191/ https://www.ncbi.nlm.nih.gov/pubmed/33121237 http://dx.doi.org/10.3324/haematol.2020.261891

Ejemplares similares

TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?
por: Bomben, Riccardo, et al.
Publicado: (2023)

KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders
por: Vendramini, Elena, et al.
Publicado: (2022)

Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond
por: Pozzo, Federico, et al.
Publicado: (2022)

KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival
por: Vendramini, Elena, et al.
Publicado: (2019)

P594: THE CXCR4-LOW/CD5-HIGH PROLIFERATIVE FRACTION IS ENRICHED IN BTK MUTATIONS AND ANTICIPATES RELAPSE IN IBRUTINIB-TREATED CLL
por: Pozzo, Federico, et al.
Publicado: (2023)

P606: MEASUREMENT OF INTRACLONAL DIVERSIFICATION REFINES THE PROGNOSTIC IMPACT OF IGHV MUTATIONS IN CLL
por: Vit, Filippo, et al.
Publicado: (2023)

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
por: Bomben, Riccardo, et al.
Publicado: (2023)

Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukemia
por: Del Poeta, Giovanni, et al.
Publicado: (2020)

The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells
por: Dal Bo, Michele, et al.
Publicado: (2015)

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application
por: Pozzo, Federico, et al.
Publicado: (2013)

Measurable residual disease in chronic lymphocytic leukemia
por: Benintende, Giulia, et al.
Publicado: (2023)

S143: NATURAL CLONAL EVOLUTION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH BIMODAL CD49D EXPRESSION REVEALS CD49D PLASTICITY
por: Tissino, Erika, et al.
Publicado: (2023)

IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia
por: Bulian, Pietro, et al.
Publicado: (2012)

An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy
por: Cohen, Jared A., et al.
Publicado: (2020)

A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia
por: Cohen, Jared A., et al.
Publicado: (2020)

Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance
por: Dal-Bo, Michele, et al.
Publicado: (2009)

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia
por: Dereani, Sara, et al.
Publicado: (2014)

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia
por: Tissino, Erika, et al.
Publicado: (2018)

Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance
por: Zucchetto, Antonella, et al.
Publicado: (2006)

P597: XPO1 MUTATIONS IDENTIFY EARLY STAGE CLL CHARACTERIZED BY SHORTER TIME TO FIRST TREATMENT AND ENHANCED BCR SIGNALING
por: Talotta, Donatella, et al.
Publicado: (2023)

Integrin Signaling Shaping BTK-Inhibitor Resistance
por: Polcik, Laura, et al.
Publicado: (2022)

Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells
por: Rossi, Francesca M, et al.
Publicado: (2010)

The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential
por: Dal Bo, Michele, et al.
Publicado: (2015)

Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia
por: Wang, Jiguang, et al.
Publicado: (2014)

VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects
por: Härzschel, Andrea, et al.
Publicado: (2020)

P608: THE EXPRESSION OF CYTOR LNCRNA HAS POOR PROGNOSTIC VALUE IN CLL PATIENTS AND IS ASSOCIATED WITH MICROENVIRONMENTAL STIMULI.
por: Hernández, Lluís, et al.
Publicado: (2023)

Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models
por: Capolla, Sara, et al.
Publicado: (2023)

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies
por: Pepper, Andrea G. S., et al.
Publicado: (2021)

HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia
por: Griggio, Valentina, et al.
Publicado: (2020)

A case of SRSF2 mutation in chronic lymphocytic leukemia
por: Garza, Eduardo, et al.
Publicado: (2016)

Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases
por: Mazzaro, Cesare, et al.
Publicado: (2018)

P1208: TRANSCRIPTOMIC PROFILING OF B CELL STATES AND MICROENVIROMENTAL ECOSYSTEMS REFINES THE PROGNOSTIC CLASSIFICATION OF DIFFUSE LARGE B CELL LYMPHOMA
por: Papotti, Robel, et al.
Publicado: (2023)

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
por: Gentile, Massimo, et al.
Publicado: (2020)

TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia
por: Szenes, Eva, et al.
Publicado: (2020)

Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation
por: Fabbri, Giulia, et al.
Publicado: (2011)

CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms
por: Hutterer, Evelyn, et al.
Publicado: (2015)

Fournier’s Gangrene Complicating Hematologic Malignancies: a Case Report and Review of Licterature
por: D’Arena, Giovanni, et al.
Publicado: (2013)

Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role
por: D'Arena, Giovanni, et al.
Publicado: (2016)

Follicular lymphoma subgroups with and without t(14;18) differ in their N-glycosylation pattern and IGHV usage
por: Leich, Ellen, et al.
Publicado: (2021)

Regulatory T-Cells in Chronic Lymphocytic Leukemia and Autoimmune Diseases
por: D’Arena, Giovanni, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_a99ppqsojdc420f55h346jklaa